Develops therapies for acute and chronic gastrointestinal diseases, focusing on novel approaches and treatment options.
Palisade Bio, Inc., headquartered in Carlsbad, California, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of oral therapies targeting severe diseases linked to the breakdown of the mucosal barrier safeguarding the gastrointestinal (GI) tract. Established in 2005, Palisade Bio focuses on advancing innovative treatments that address critical medical needs within the GI space. At the forefront of its portfolio is LB1148, an oral liquid formulation of tranexamic acid, a digestive enzyme inhibitor designed to mitigate abdominal adhesions in GI tissues and expedite post-surgical bowel function recovery.
LB1148 represents Palisade Bio's primary therapeutic candidate, demonstrating the company's commitment to pioneering solutions that enhance patient outcomes and quality of life. By concentrating on conditions involving GI mucosal barrier dysfunction, Palisade Bio aims to fill significant treatment gaps and improve healthcare options for patients facing these challenging diseases. The company leverages its expertise in biopharmaceutical development to advance LB1148 and other promising candidates through rigorous clinical trials and regulatory processes, positioning itself as a leader in gastrointestinal healthcare innovation.
With a robust foundation built on scientific expertise and strategic development initiatives, Palisade Bio continues to expand its pipeline of novel oral therapies. Through ongoing research and partnerships, the company remains dedicated to transforming the treatment landscape for GI-related disorders, reaffirming its commitment to advancing medical science and improving patient care globally.